173 related articles for article (PubMed ID: 11388646)
41. Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease.
von Vigier RO; Zberg PM; Teuffel O; Bianchetti MG
Eur J Pediatr; 2000 Aug; 159(8):590-3. PubMed ID: 10968237
[TBL] [Abstract][Full Text] [Related]
42. Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy.
Nakamura T; Ushiyama C; Suzuki S; Shimada N; Sekizuka K; Ebihara I; Takahashi Y; Tanaka A; Koide H
Nephron; 2000 Oct; 86(2):247. PubMed ID: 11015024
[No Abstract] [Full Text] [Related]
43. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats.
Yoshimoto T; Naruse M; Nishikawa M; Naruse K; Tanabe A; Seki T; Imaki T; Demura R; Aikawa E; Demura H
Am J Physiol; 1997 Jun; 272(6 Pt 1):E989-96. PubMed ID: 9227442
[TBL] [Abstract][Full Text] [Related]
44. Differential effects of enalapril and irbesartan in experimental papillary necrosis.
Garber SL; Mirochnik Y; Arruda JA; Dunea G; Slobodskoy L
Kidney Blood Press Res; 2001; 24(1):39-43. PubMed ID: 11174005
[TBL] [Abstract][Full Text] [Related]
45. Angiotensin II receptor antagonist improves age-related endothelial dysfunction.
Kansui Y; Fujii K; Goto K; Abe I; Iida M
J Hypertens; 2002 Mar; 20(3):439-46. PubMed ID: 11875311
[TBL] [Abstract][Full Text] [Related]
46. Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.
Eberhard R; Dikow R
Ann Med; 2002; 34(7-8):507-13. PubMed ID: 12553490
[TBL] [Abstract][Full Text] [Related]
47. Angiotensin II and its receptors in the diabetic kidney.
Burns KD
Am J Kidney Dis; 2000 Sep; 36(3):449-67. PubMed ID: 10977776
[TBL] [Abstract][Full Text] [Related]
48. Role of the renin-angiotensin system in hypertension in the elderly.
Nagano M; Higaki J; Mikami H; Ogihara T
Blood Press Suppl; 1994; 5():130-3. PubMed ID: 7889195
[TBL] [Abstract][Full Text] [Related]
49. Suppression of endotoxin-induced renal tumor necrosis factor-alpha and interleukin-6 mRNA by renin-angiotensin system inhibitors.
Niimi R; Nakamura A; Yanagawa Y
Jpn J Pharmacol; 2002 Feb; 88(2):139-45. PubMed ID: 11928713
[TBL] [Abstract][Full Text] [Related]
50. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats.
Kalender B; Oztürk M; Tunçdemir M; Uysal O; Dagistanli FK; Yegenaga I; Erek E
Acta Histochem; 2002; 104(2):123-30. PubMed ID: 12086332
[TBL] [Abstract][Full Text] [Related]
51. Effects of chronic inhibition of ACE and AT1 receptors on glomerular injury in dahl salt-sensitive rats.
Otsuka F; Yamauchi T; Kataoka H; Mimura Y; Ogura T; Makino H
Am J Physiol; 1998 Jun; 274(6):R1797-806. PubMed ID: 9841488
[TBL] [Abstract][Full Text] [Related]
52. Hyperlipidaemia and the progression of nephropathy in OLETF rats: effect of angiotensin-converting enzyme inhibitor, enalapril.
Sugimoto K; Tsuruoka S; Fujimura A
Clin Exp Pharmacol Physiol; 1999 Aug; 26(8):601-7. PubMed ID: 10474773
[TBL] [Abstract][Full Text] [Related]
53. Effects of the non-peptide angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension.
Ito K; Shiomi M; Kito G
Hypertens Res; 1995 Mar; 18(1):69-75. PubMed ID: 7584913
[TBL] [Abstract][Full Text] [Related]
54. Angiotensin II subtype-1 receptor antagonists improve hemodynamic and renal changes without affecting glucose metabolisms in genetic rat model of non-insulin-dependent diabetes mellitus.
Uehara Y; Hirawa N; Kawabata Y; Numabe A; Gomi T; Ikeda T; Omata M
Am J Hypertens; 1999 Jan; 12(1 Pt 1):21-7. PubMed ID: 10075380
[TBL] [Abstract][Full Text] [Related]
55. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB.
Onozato ML; Tojo A; Goto A; Fujita T; Wilcox CS
Kidney Int; 2002 Jan; 61(1):186-94. PubMed ID: 11786100
[TBL] [Abstract][Full Text] [Related]
56. Coinhibition of immune and renin-angiotensin systems reduces the pace of glomerulosclerosis in the rat remnant kidney.
Hamar P; Peti-Peterdi J; Rázga Z; Kovács G; Heemann U; Rosivall L
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S234-8. PubMed ID: 9892170
[TBL] [Abstract][Full Text] [Related]
57. The renin-angiotensin system blockade does not prevent renal interstitial fibrosis induced by aristolochic acids.
Debelle FD; Nortier JL; Husson CP; De Prez EG; Vienne AR; Rombaut K; Salmon IJ; Deschodt-Lanckman MM; Vanherweghem JL
Kidney Int; 2004 Nov; 66(5):1815-25. PubMed ID: 15496152
[TBL] [Abstract][Full Text] [Related]
58. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?
Gansevoort RT; de Zeeuw D; de Jong PE
Kidney Int; 1994 Mar; 45(3):861-7. PubMed ID: 8196289
[TBL] [Abstract][Full Text] [Related]
59. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus.
Rizzoni D; Porteri E; De Ciuceis C; Sleiman I; Rodella L; Rezzani R; Paiardi S; Bianchi R; Ruggeri G; Boari GE; Muiesan ML; Salvetti M; Zani F; Miclini M; Rosei EA
Hypertension; 2005 Apr; 45(4):659-65. PubMed ID: 15723969
[TBL] [Abstract][Full Text] [Related]
60. V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.
Perico N; Zoja C; Corna D; Rottoli D; Gaspari F; Haskell L; Remuzzi G
Kidney Int; 2009 Nov; 76(9):960-7. PubMed ID: 19625993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
